HPLC method for the development and validation of busulfan in pharmaceutical formulation
DOI:
https://doi.org/10.30574/gscarr.2021.6.3.0051Keywords:
Busulfan (BUS), HPLC, ICH Q2 (R1), RecoveryAbstract
A validated HPLC method was developed for the determination of Busulfan (BUS) in pharmaceutical formulation.It is a new simple, accurate, precise and reproducible HPLC method has been developed for the estimation of Busulfan (1,4-butanediol dimethanesulfonate) in its inject able dosage.The method developed in High Performance Liquid Chromatographic method using suitable column (YMC Pack ODS-A (150 x 4.6) mm, 3µm). All the components of the system are controlled using SCL-10Avp System Controller. Data acquisition was done using LC Solutions software.The method was validated as per the ICH guidelines. Thus, the proposed HPLC method can be successfully applied for the routine quality control analysis of formulations. The method developed is simple and is better than the methods reported in the literature and the method is capable to give a good detector response, the recovery calculated was within the range of 98% to 102% of the specification limits.
Metrics
References
Warwick GP. Cancer Res. 1963; 23: 1315-33.
Lesurtel M, Graf R, Aleil B, Walther D, Tian Y, Jochum W, Gachet C, Bader M, Clavien P. Platelet-derived serotonin mediates liver regeneration. Science. 2006; 312 (5770): 104–7.
Grigg A, Gibson R, Bardy P, Szer J. Acute portal vein thrombosis after autologous stem cell transplantation. Bone Marrow Transplant. 1996; 18 (5): 949–53.
Brisse H, Orbach D, Lassau N, Servois V, Doz F, Debray D, Helfre S, Hartmann O, Neuenschwander S. Portal vein thrombosis during antineoplastic chemotherapy in children: report of five cases and review of the literature". Eur. J. Cancer. 2004; 40(18): 2659–66.
Bhagwatwar HP, Phadungpojna S, Chow DS-L, Andersson BS. Cancer Chemother Pharmacol. 1996; 37: 401-8.
Andersson BS, Madden T, Tran HT et al. Biol Blood Marrow Transplant. 2000; 6: 548-54.
Andersson BS, Kashyap A, Gian V et al. Biol Blood Marrow Transplant. 2002; 8: 145-54.
GlaxoSmithKline. Prescribing information leaflet: Myleran (busulfan) tablets. 2004.
Sweetman SC, editor. Busulfan. In: Martindale: the Complete Drug Reference, 34th ed. London: Pharmaceutical Press. 2005.
Thomson Healthcare. Physicians’ Desk Reference, 62nd ed. Montvale, NJ: Thomson. 2008.
Iwamoto T, Hiraku Y, Oikawa S, et al. DNA intrastrand cross-link at the 5′-GA-3′ sequence formed by busulfan and its role in the cytotoxic effect. Cancer Sci. 2004; 95: 454–458.
Morales-Ramírez P, Miranda-Pasaye S, Cruz-Vallejo VL, et al. Kinetic of genotoxic expression in the pharmacodynamics of busulfan. Arch Med Res. 2006; 37: 316–321.
Bishop JB, Wassom JS. Toxicological review of busulfan (Myleran). Mutat Res. 1986; 168: 15–45.
Sanderson BJ, Shield AJ. Mutagenic damage to mammalian cells by therapeutic alkylating agents. Mutat Res. 1996; 355: 41–57.
ICH. Q2A Text on Validation of Analytical Procedures, International Conference on Harmonization. Oct, 1994.
ICH. Q3B Validation of Analytical Procedures: Methodology, International Conference on Harmonization. Nov, 1996.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2021 Sekhar K Swamy, Ch Venkata kishore, V Tejeswara Rao, K. Raghu Babu
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
